ANIP vs URGN: stock comparison and AI forecast
Ani Pharmaceuticals Inc (ANIP) and Urogen Pharma Ltd. (URGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ANIP Ani Pharmaceuticals Inc
- Market Cap
- $1.66B
- P/E Ratio
- 13.7x
- Size
- small-cap
- AI Forecast
URGN Urogen Pharma Ltd.
- Market Cap
- $1.68B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ANIP and URGN have similar market capitalizations ($1.66B and $1.68B).
- ANIP turns 734.8% of its revenue into net income, against -51.7% for URGN.
- ANIP yields 0.02% in dividends; URGN pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ANIP | URGN |
|---|---|---|
| Market Cap | $1.66B | $1.68B |
| P/E Ratio | 13.66x | – |
| P/B Ratio | 2.78x | – |
| Dividend Yield | 0.02% | – |
| EPS | $5.29 | – |
| Book Value/Share | $26.01 | – |
| Revenue/Share | $0.64 | $3.86 |
| FCF/Share | $7.53 | $-3.26 |
Profitability & Margins
| Metric | ANIP | URGN |
|---|---|---|
| ROE | 18.1% | – |
| ROA | 7.2% | -38.6% |
| ROIC | 12.4% | -35.0% |
| Gross Margin | -2528.2% | 91.8% |
| Operating Margin | 1020.0% | -35.3% |
| Net Margin | 734.8% | -51.7% |
| EBT Margin | 967.4% | -52.0% |
| Tax Rate | 24.0% | 0.5% |
Financial Health
| Metric | ANIP | URGN |
|---|---|---|
| Current Ratio | 2.91x | 3.80x |
| Quick Ratio | 2.41x | 3.41x |
| D/E Ratio | 1.50x | – |
| Financial Leverage | 2.50x | – |
| Interest Coverage | 5.4x | -18.7x |
| Working Capital | $542M | $174M |
Cash Flow
| Metric | ANIP | URGN |
|---|---|---|
| Operating Cash Flow | $189M | -$159M |
| Free Cash Flow | $173M | -$159M |
| Capital Spending | -$16M | -$220K |
| OCF Growth YoY | 36.2% | – |
| FCF Growth YoY | 37.9% | – |
| FCF/Sales | 1173.6% | -84.3% |
| CapEx/Sales | 111.8% | 0.1% |
Operational Efficiency
| Metric | ANIP | URGN |
|---|---|---|
| Asset Turnover | 0.01x | 0.75x |
| Receivables Turnover | 0.1x | 2.1x |
| Inventory Turnover | 2.7x | 0.6x |
| Fixed Assets Turnover | 0.2x | 316.1x |
| Days Sales Outstanding | 6797 days | 172 days |
| Days Inventory | 135 days | 580 days |
| Payables Period | 70 days | 365 days |
| Cash Conversion Cycle | 6862 days | 387 days |
Income Statement
| Metric | ANIP | URGN |
|---|---|---|
| Total Revenue | $15M | $189M |
| Operating Income | $150M | -$67M |
| Net Income | $108M | -$98M |
| R&D Expense | $50M | $61M |
| SG&A Expense | $325M | $177M |
| Cost of Goods Sold | $387M | $15M |
Dividend & Shareholder Information
| Metric | ANIP | URGN |
|---|---|---|
| Dividends Per Share | $0.01 | – |
| Payout Ratio | 0.2% | – |
| Shares Outstanding | 23M | 49M |
| Net Income Growth | 6358.4% | – |
ANIP vs URGN: stock comparison and AI forecast
Which is bigger, ANIP or URGN?
ANIP and URGN have similar market capitalizations ($1.66B and $1.68B).
Which one does Intratio's AI model rank higher, ANIP or URGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.